甲氧氯普胺鼻喷剂治疗女性症状性糖尿病胃轻瘫:一项随机、双盲、安慰剂对照3期研究
这项美国多中心3期研究将205例女性糖尿病胃轻瘫患者随机分为安慰剂组(n=103)和甲氧氯普胺鼻喷剂10mg组(n=102),主要终点(第4周胃轻瘫症状评估每日总评分较基线变化)两组无显著差异(P=.881);但基线中重度症状患者第1至3周有显著治疗效应(P<.05),且全部4周恶心和上腹痛较安慰剂显著减轻(P<.05)。治疗中出现的不良事件主要为轻中度,最常见为头痛和腹痛。
要点
- 总体人群中甲氧氯普胺鼻喷剂10mg与安慰剂相比第4周主要终点无显著差异(P=.881)。
- 基线中重度症状女性第1至3周有显著治疗效应(P<.05),全部4周恶心和上腹痛显著减轻(P<.05)。
- 治疗中出现的不良事件主要为轻中度,最常见为头痛和腹痛,安全性特征与安慰剂相似。
核心结论
- 尽管全部入组患者的主要终点未达到,甲氧氯普胺鼻喷剂治疗为基线中重度症状的女性糖尿病胃轻瘫患者提供了显著的症状缓解。
- 甲氧氯普胺鼻喷剂耐受性良好,安全性特征与安慰剂相似。
研究设计与样本
- 美国多中心、随机、双盲、平行分组3期研究,纳入18-75岁伴胃排空延迟的女性糖尿病胃轻瘫患者。
- 受试者按1:1随机接受安慰剂或甲氧氯普胺鼻喷剂10mg。
- 主要疗效终点为每日胃轻瘫症状评估总评分均值从基线至第4周的变化。
- 胃轻瘫症状评估每日日记为经过验证的患者报告结局工具,对恶心、早饱、持续饱胀、腹胀和上腹痛按5点有序量表取平均分。
主要发现
- 共205例受试者随机分组:安慰剂组n=103,甲氧氯普胺鼻喷剂组n=102。
- 总体而言,甲氧氯普胺鼻喷剂组从基线至第4周的症状减轻与安慰剂组相比无显著差异(P=.881)。
- 基线中重度症状的受试者第1至3周有显著治疗效应(P<.05)。
- 基线中重度症状的受试者全部4周恶心和上腹痛较安慰剂显著减轻(P<.05)。
- 治疗中出现的不良事件主要为轻中度,头痛和腹痛报告最频繁。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metoclopramide nasal spray (MNS) was developed as an alternative to oral metoclopramide. Prior phase 2 studies demonstrated efficacy in reducing symptoms in women, but not men with diabetic gastroparesis. The aim of this phase 3 study was to further determine the safety and efficacy of MNS compared with placebo in reducing symptoms of diabetic gastroparesis in women. METHODS: This US multicenter, randomized, double-blind, parallel group study enrolled women aged 18-75 years with diabetic gastroparesis and delayed gastric emptying. Subjects were randomized 1:1 to receive placebo or MNS 10 mg. The primary efficacy end point was change in mean daily Gastroparesis Symptom Assessment total score from baseline to Week 4. The Gastroparesis Symptom Assessment daily diary is a validated patient-reported outcome instrument that averages scores of nausea, early satiety, prolonged fullness, bloating, and upper abdominal pain on a 5-point ordinal scale. RESULTS: Two hundred and five subjects were randomized to receive placebo (n = 103) or MNS (n = 102). Overall, the MNS group did not experience a significant reduction in symptoms compared with the placebo group from baseline to Week 4 (P = .881). However, subjects with moderate-to-severe symptoms at baseline had a significant treatment effect from Weeks 1 to 3 (P < .05) and experienced a significant reduction in nausea and upper abdominal pain for all 4 weeks versus placebo (P < .05). Treatment-emergent adverse events were primarily mild to moderate with headache and abdominal pain reported most frequently. CONCLUSIONS: Although the primary end point was not met using all enrolled patients, treatment with MNS provided significant relief for women with moderate-to-severe diabetic gastroparesis symptoms. MNS was well tolerated and demonstrated a similar safety profile to placebo. (ClinicalTrials.gov identifier: NCT02025725.).
引用
- McCallum RW, Parkman HP, Fass R, et al. Metoclopramide Nasal Spray in Women With Symptomatic Diabetic Gastroparesis: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. Clin Gastroenterol Hepatol. 2023. PMID: 37924856. doi:10.1016/j.cgh.2023.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。